PDF(Pubmed)
Abstract：
OBJECTIVE: To evaluate trends in the incidence and survival outcomes of endometrial cancer (EC) based on the year of diagnosis, stage, age, and histologic types.
METHODS: Women with primary EC diagnosed between 1999 and 2018, and who were followed up with until 2019, were identified from the Korea Central Cancer Registry using the International Classification of Diseases, 10th revision. The age-standardized rates (ASRs) of incidence, annual percent changes (APCs), and survival were estimated according to age, stage, histology, and year of diagnosis.
RESULTS: The ASR for EC increased from 2.38 per 100,000 in 1999 to 7.29 per 100,000 in 2018 across all histologic types (APCs of 9.82, 15.97, and 7.73 for endometrioid, serous, and clear cell, respectively, p<0.001). There were significant differences in the 5-year survival rates based on histology (90.9%, 55.0%, and 68.5% for endometrioid, serous, and clear cell, respectively, p<0.001), stage (93.4%, 77.0%, and 31.0% for localized, regional, and distant, respectively, p<0.001), and age (93.0% for <50 years and 80.6% for ≥50 years, p<0.001). The 5-year survival was significantly better in the group diagnosed between 2000 and 2018 (85.9%) than that in the 1999-2008 group (83.3%) (p<0.001). This trend was only observed for endometrioid cancer (p<0.001).
CONCLUSIONS: The incidence of EC increased across the all 3 subtypes. Survival of patients with endometrioid histology improved over the past two decades, but remained static for serous or clear cell histology. Healthcare strategies to prevent EC incidence in at-risk populations and apply effective treatments for high-risk histology are needed.
METHODS: Women with primary EC diagnosed between 1999 and 2018, and who were followed up with until 2019, were identified from the Korea Central Cancer Registry using the International Classification of Diseases, 10th revision. The age-standardized rates (ASRs) of incidence, annual percent changes (APCs), and survival were estimated according to age, stage, histology, and year of diagnosis.
RESULTS: The ASR for EC increased from 2.38 per 100,000 in 1999 to 7.29 per 100,000 in 2018 across all histologic types (APCs of 9.82, 15.97, and 7.73 for endometrioid, serous, and clear cell, respectively, p<0.001). There were significant differences in the 5-year survival rates based on histology (90.9%, 55.0%, and 68.5% for endometrioid, serous, and clear cell, respectively, p<0.001), stage (93.4%, 77.0%, and 31.0% for localized, regional, and distant, respectively, p<0.001), and age (93.0% for <50 years and 80.6% for ≥50 years, p<0.001). The 5-year survival was significantly better in the group diagnosed between 2000 and 2018 (85.9%) than that in the 1999-2008 group (83.3%) (p<0.001). This trend was only observed for endometrioid cancer (p<0.001).
CONCLUSIONS: The incidence of EC increased across the all 3 subtypes. Survival of patients with endometrioid histology improved over the past two decades, but remained static for serous or clear cell histology. Healthcare strategies to prevent EC incidence in at-risk populations and apply effective treatments for high-risk histology are needed.
摘要：
目的：根据诊断年份评估子宫内膜癌（EC）的发病率和生存结局的趋势，舞台,年龄,和组织学类型。
方法：在1999年至2018年之间诊断为原发性EC的女性，并随访至2019年，从韩国中央癌症注册中心使用国际疾病分类进行鉴定。第十次修订。发病率的年龄标准化率(ASR)，年度百分比变化(APC)，存活率是根据年龄估计的，舞台,组织学,和诊断年份。
结果：在所有组织学类型中，EC的ASR从1999年的2.38/100,000增加到2018年的7.29/100,000（子宫内膜样的APC为9.82、15.97和7.73，浆液,和透明细胞，分别,p<0.001)。基于组织学的5年生存率存在显着差异（90.9％，55.0%,子宫内膜样为68.5%，浆液,和透明细胞，分别,p<0.001)，阶段(93.4%，77.0%,本地化率为31.0%，区域,遥远,分别,p<0.001)，和年龄(<50岁为93.0%，≥50岁为80.6%，p<0.001)。2000年至2018年诊断组的5年生存率（85.9％）明显优于1999年至2008年诊断组（83.3％）（p<0.001）。这种趋势仅在子宫内膜样癌中观察到(p<0.001)。
结论：在所有3种亚型中，EC的发病率均增加。在过去的二十年中，子宫内膜样组织学患者的生存率有所改善，但对浆液性或透明细胞组织学保持静态。需要采取医疗保健策略来预防高危人群的EC发病率，并对高危组织学进行有效的治疗。
方法：在1999年至2018年之间诊断为原发性EC的女性，并随访至2019年，从韩国中央癌症注册中心使用国际疾病分类进行鉴定。第十次修订。发病率的年龄标准化率(ASR)，年度百分比变化(APC)，存活率是根据年龄估计的，舞台,组织学,和诊断年份。
结果：在所有组织学类型中，EC的ASR从1999年的2.38/100,000增加到2018年的7.29/100,000（子宫内膜样的APC为9.82、15.97和7.73，浆液,和透明细胞，分别,p<0.001)。基于组织学的5年生存率存在显着差异（90.9％，55.0%,子宫内膜样为68.5%，浆液,和透明细胞，分别,p<0.001)，阶段(93.4%，77.0%,本地化率为31.0%，区域,遥远,分别,p<0.001)，和年龄(<50岁为93.0%，≥50岁为80.6%，p<0.001)。2000年至2018年诊断组的5年生存率（85.9％）明显优于1999年至2008年诊断组（83.3％）（p<0.001）。这种趋势仅在子宫内膜样癌中观察到(p<0.001)。
结论：在所有3种亚型中，EC的发病率均增加。在过去的二十年中，子宫内膜样组织学患者的生存率有所改善，但对浆液性或透明细胞组织学保持静态。需要采取医疗保健策略来预防高危人群的EC发病率，并对高危组织学进行有效的治疗。
